{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:08Z","timestamp":1790285948517,"version":"4.1.0"},"reference-count":7,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Factor XIa (FXIa) may be involved in thrombus formation, but only to a lesser extent involved in haemostasis. Several novel FXIa inhibitors are under investigation, and Phase II trials demonstrated marked reduction of bleeding compared with standard treatment by factor Xa inhibitors. Asundexian is a small molecule that selectively inhibits FXIa. A large-scale Phase III clinical trial, OCEANIC-AF, has been initiated to compare the efficacy and safety between asundexian and apixaban. However, the OCEANIC-AF study was recently halted due to the inferior efficacy of asundexian versus the apixaban control arm. The present report describes up-to-date evidence of FXIa inhibitors and discusses the future position of FXIa inhibitors for patients with AF.<\/jats:p>","DOI":"10.15420\/ecr.2023.50","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:38:41Z","timestamp":1719844721000},"source":"Crossref","is-referenced-by-count":5,"title":["What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8827-3315","authenticated-orcid":false,"given":"Maki","family":"Komiyama","sequence":"first","affiliation":[{"name":"Division of Translational Research, NHO Kyoto Medical Centre, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-1203","authenticated-orcid":false,"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiac Rehabilitation, NHO Kyoto Medical Centre, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-224X","authenticated-orcid":false,"given":"Hiromichi","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Translational Research, NHO Kyoto Medical Centre, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0096-438X","authenticated-orcid":false,"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-2582","authenticated-orcid":false,"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Romanian Academy of Scientists, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-4043","authenticated-orcid":false,"given":"Koji","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Translational Research, NHO Kyoto Medical Centre, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med 2021;385:2161\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2113194; PMID: 34780683.","DOI":"10.1056\/nejmoa2113194"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hasegawa K, Ikeda T. Pharmapulse report-does the arrival of factor XI inhibitors mark the end of the NOAC era? Eur Heart J Cardiovasc Pharmacother 2022;8:E9. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac003; PMID: 35088076.","DOI":"10.1093\/ehjcvp\/pvac003"},{"key":"ref2","unstructured":"Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022;399:1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1; PMID: 35385695."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017;103:623\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2016-309901; PMID: 27798052.","DOI":"10.1136\/heartjnl-2016-309901"},{"key":"ref4","unstructured":"Ruff CT. AZALEA-TIMI 71: a multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation. Presented at: American Heart Association Scientific Sessions, Philadelphia, PA, US, 11 November 2023."},{"key":"ref5","unstructured":"Bayer Global. OCEANIC-AF study stopped early due to lack of efficacy. 2023. https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/ (accessed 4\u00a0December 2023)."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020;383:1735\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2012883; PMID: 32865374.","DOI":"10.1056\/nejmoa2012883"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:38:47Z","timestamp":1719844727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":7,"URL":"https:\/\/doi.org\/10.15420\/ecr.2023.50","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"e10"}}